Multiple phase III trials assessing the role of an EGFR-TKI for resected EGFR-mutated NSCLC are currently ongoing, including ICWIP (NCT02125240), APEX (NCT04762459), FORWARD (NCT04853342), ADAURA2 (NCT05120349), and BD-BF-III01 (NCT06041776). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.